LDN193189 (Tetrahydrochloride)

LDN193189 (Tetrahydrochloride)

• Product Name Alternative: DM-3189 (Tetrahydrochloride)
• CAS Number: 2310134-98-4
• UNSPSC Description: LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM)[1].
• Target Antigen: Organoid; TGF-β Receptor
• Type: Reference compound
• Related Pathways: Stem Cell/Wnt;TGF-beta/Smad
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/LDN193189-Hydrochloride.html
• Purity: 99.86
• Solubility: DMSO : 4.17 mg/mL (ultrasonic)|H2O : 33.33 mg/mL (ultrasonic)
• Smiles: C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16.Cl.Cl.Cl.Cl
• Molecular Weight: 552.33
• References & Citations: [1]Yu PB, et al. BMP type I receptor inhibition reduces heterotopic [corrected] ossification. Nat Med, 2008, 14(12), 1363-1369.|[2]Lee YC, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res, 2011, 71(15), 5194-5203.|[3]Yang L, et al. UK-92480 increases connexin 40 in smooth muscle cells through activation of BMP pathways in pulmonary arterial hypertension. Int J Clin Exp Pathol. 2014 Jul 15;7(8):4674-84.bioRxiv. 2024 July 03.|Cancer Lett. 2020 Jan 28;469:390-398.|Cell Rep. 2017 Aug 29;20(9):2227-2237. |Cell Rep. 2017 Aug 29;20(9):2227-2237. |Curr Protoc Cell Biol. 2018 Dec;81(1):e62.|Diabetes. 2020 Apr;69(4):634-646.|EMBO Rep. 2023 Jul 26;e56454.|Harvard Medical School LINCS LIBRARY|Nature. 2022 May;605(7909):325-331.|Patent. US20180263995A1.|Prostate. 2021 Sep 23.|Stem Cell Res Ther. 2021 Jun 11;12(1):345.|Adv Sci (Weinh). 2024 Jan 18:e2308072.|Biochim Biophys Acta Gen Subj. 29 October 2021, 130046.|Biomaterials. 2020 May;240:119849.|Biomedicines. 2022 Apr 18;10(4):928. |bioRxiv. 2024 Aug 6:2024.08.05.606734.|bioRxiv. 2024 Jul 11:2024.07.08.602611.|bioRxiv. 2024 Mar 13.|bioRxiv. 2024 Mar 25.|bioRxiv. 2024 November 15.|bioRxiv. 2024 November 28.|bioRxiv. 2024 Oct 9:2024.10.08.617155.|Cancer Metab. 2023 Jul 13;11(1):9.|Cardiovasc Toxicol. 2019 Jun;19(3):264-275. |Cell Commun Signal. 2024 May 30;22(1):300.|Cell Rep Methods. 2024 May 8:100777.|Cell Rep. 2023 Dec 5;42(12):113541.|Cell Transplant. 2024 Jan-Dec:33:9636897241288932.|EMBO Rep. 2023 Jul 26;e56454.|Eur Respir J. 2021 Dec 2;2100327.|Exp Ther Med. 2019 Apr;17(4):2648-2656. |Front Cell Dev Biol. 13 May 2021.|Front Mol Biosci. 2021 Apr 26;8:663987.|Front Mol Biosci. 2021; 8: 663987.|Int J Mol Sci. 2022, 23(23), 14831.|Int J Mol Sci. 2024 Apr 9, 25(8), 4138.|Int J Ophthalmol. 2022 May 18;15(5):711-720.|Int J Stem Cells. 2023 May 30;16(2):156-167.|iScience. 2019 Sep 27;19:1248-1259.|iScience. 2022 Dec 26;26(1):105898.|iScience. 2024 Feb 5;27(3):109111.|J Hazard Mater. 2023 Nov 19, 133028.|J Recept Signal Transduct Res. 2017 Oct;37(5):515-521.|Mar Drugs. 2022 Nov 14;20(11):715.|Mol Cell. 2022 Jun 3;S1097-2765(22)00480-4.|Oxid Med Cell Longev. 2020 Jun 8;2020:4175613.|Patent. US20210346386A1.|Patent. US20240247230A1.|Pigment Cell Melanoma Res. 2023 Aug 9.|Res Sq. 2024 Nov 14.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2023 May 17.|Sci Rep. 2022 Mar 18;12(1):4740.|Sci Rep. 2022 Mar 25;12(1):5221.|Stem Cell Res Ther. 2022 Aug 19;13(1):424.|Stem Cell Res Ther. 2022 Sep 2;13(1):436.|Stem Cell Res Ther. 2023 Jan 5;14(1):1.|Stem Cell Res Ther. 2024 Dec 18;15(1):478.|Stem Cells Int. 2022 Apr 28;2022:1560943.|Stem Cells Int. 22 Dec 2022.|Stem Cells. 2023 Apr 8;sxad028.|Transl Oncol. 2019 Dec 19;13(2):125-134
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture)
• Clinical Information: No Development Reported